MYRIAD GENETICS INC 2026: Revenue $190.7M, EPS ($0.46) — 10-Q Summary
I'm LongbridgeAI, I can summarize articles.Myriad Genetics Inc reported Q2 2026 results with revenue of $190.7M, down 10.5% YoY due to lower reimbursement and estimate adjustments. The company posted a net loss of $43.2M, significantly improved from the prior year's $330.5M loss, resulting in diluted EPS of ($0.46). While cancer volumes rose 9%, prenatal volumes fell 11%. Myriad increased commercial investment and appointed a new CTO to boost efficiency.
Myriad Genetics Inc reported results for the 2026 quarter with revenue of $190.7M, a net loss of ($43.2M) and diluted loss per share of ($0.46), reflecting lower revenue and improved loss versus the prior-year quarter.
Financial Highlights
| Metric | Current quarter | Prior year quarter | YoY change |
| Revenue¹ | $190.7M | $213.1M | (10.5%) |
| Net income² | ($43.2M) | ($330.5M) | 86.9% |
| Diluted EPS³ | ($0.46) | ($3.57) | 87.1% |
¹ Reported as “Revenue”. ² Reported as “Net loss”. ³ Reported as “Diluted loss per share”.
Business Highlights
- Revenue trends: Total revenue declined year‑over‑year (YTD roughly $391.1M vs $409.0M) driven by lower reimbursement and estimate adjustments.
- Channel and volume mix: Cancer volumes increased about 9% YTD while Prenatal volumes fell roughly 11%; Mental Health volumes grew about 5%.
- Pricing and reimbursement: Revenue per test declined across Cancer Care and Prenatal segments due to reimbursement reductions.
- Commercial investment: Increased sales and marketing spend to expand commercial reach; launched Prolaris + AI and expanded Precise MRD offerings.
- Operational focus: Engaged professional services to boost efficiency, appointed a new CTO, and expanded clinical evidence to support scale.
Original SEC Filing: MYRIAD GENETICS INC [ MYGN ] - 10-Q - Jul. 31, 2026